Dunger D B, Seckl J R, Lightman S L
J Clin Endocrinol Metab. 1987 Jan;64(1):185-9. doi: 10.1210/jcem-64-1-185.
Patients with essential hypernatremia maintain urinary concentrating ability despite plasma hyperosmolality and low plasma vasopressin concentrations. We investigated renal sensitivity to ultralow dose vasopressin infusions in two patients with a syndrome of hypodipsia, hypernatremia with selective osmoreceptor dysfunction, early puberty, and aggressive behavior. The patients were water loaded until a hypotonic diuresis was established. Vasopressin was infused in stepwise increments from 0.4-12 fmol/kg X min. Both patients had increased renal sensitivity to vasopressin, achieving negative free water clearance at infusion rates of 0.4 and 4 fmol/kg X min (normal greater than or equal to 6). Treatment for 3 months with 1-desamino-8-D-arginine vasopressin (DDAVP) led to an improvement in behavior and the reporting, for the first time, of a sensation of thirst. After DDAVP therapy both patients had a reduction of their renal sensitivity to infused vasopressin. We conclude that untreated patients with essential hypernatremia have increased renal sensitivity to vasopressin which is reduced by DDAVP administration.
原发性高钠血症患者尽管血浆渗透压升高且血浆血管加压素浓度降低,但仍保持尿液浓缩能力。我们研究了两名患有低渗性多尿症、伴有选择性渗透压感受器功能障碍的高钠血症、性早熟和攻击性行为综合征患者对超低剂量血管加压素输注的肾脏敏感性。给患者补充水分直至建立低渗性利尿。血管加压素以0.4 - 12 fmol/kg×min的剂量逐步递增输注。两名患者对血管加压素的肾脏敏感性均增加,在输注速率为0.4和4 fmol/kg×min时实现了负的自由水清除率(正常情况下大于或等于6)。用1 - 去氨基 - 8 - D - 精氨酸血管加压素(DDAVP)治疗3个月导致行为改善,并且首次报告有口渴感。DDAVP治疗后,两名患者对输注血管加压素的肾脏敏感性均降低。我们得出结论,未经治疗的原发性高钠血症患者对血管加压素的肾脏敏感性增加,而DDAVP给药可降低这种敏感性。